No annual revenue total was found in BioVie Inc.'s SEC filings.
BioVie Inc. (BIVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.0 million in cash and investments and $275,430 in total debt.
Revenue
—
Net income (TTM)
$-529,784
Operating cash flow
$-19.02M
+0.0% vs prior year
Free cash flow
—
EPS
$-3.05
+74.8% vs prior year
Dividend per share
None
Shares outstanding
7.54M
+0.1% vs prior year
Net cash
$8.70M
FY 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIVI (Nasdaq), BIVIW (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Carson City, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1580149
- Former names
- NANOANTIBIOTICS, INC. (until Jul 22, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$22.7M | -$18.1M | -$32.2M | -$45.1M | -$27.3M |
| Net income | -$22.1M | -$17.5M | -$32.1M | -$50.3M | -$26.1M |
| Diluted EPS | -$3.05 | -$12.12 | -$73.05 | -$15.47 | -$1.06 |
| Operating cash flow | -$19.0M | -$19.0M | -$27.9M | -$40.3M | -$19.0M |
| Total assets | $14.3M | $21.6M | $25.2M | $35.1M | $20.1M |
| Total liabilities | $4.0M | $2.6M | $9.7M | $19.8M | $16.4M |
| Stockholders' equity | $10.3M | $19.0M | $15.5M | $15.3M | $3.7M |
| Cash and investments | $9.0M | $17.5M | $23.8M | $19.5M | $18.6M |
| Total debt | $275,430 | $349,894 | $410,237 | $87,414 | $126,298 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 14, 2026 | Sep 11, 2026 |
| 10-K | Annual report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 6, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 13, 2025 | Nov 10, 2025 |
All 505 BioVie Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.